International Journal of Integrative Dental and Medical Sciences (IJIDMS)
Website: https://ijidms.com/
ISSN: 3049-4222
Vol. 1, Issue 4, Sept-Oct, 2025
Page No.: 16-23

Review

Molecular Crosstalk Between Chronic Inflammation and Cancer Development

Sravani Boyapati

Associate Professor, Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Andhra Pradesh -531162

Corresponding Author:
Dr. Sravani Boyapati

Email:
savitabvcop@gmail.com

Conflict of interest: *NIL*

Article History
Received: 03/09/2025
Accepted: 22/09/2025
Published: 28/10/2025

Abstract:
Chronic inflammation is increasingly recognized as a critical driver of cancer development, contributing to tumor initiation, progression, and metastasis. The molecular crosstalk between chronic inflammation and cancer involves complex signaling networks that alter cellular behavior and the tumor microenvironment. Inflammatory mediators, such as cytokines, chemokines, and growth factors, activate signaling pathways like NF-κB, JAK-STAT, and MAPK, which promote cell proliferation, survival, angiogenesis, and immune evasion. Additionally, chronic inflammation leads to the accumulation of reactive oxygen and nitrogen species, which induce DNA damage, further driving genomic instability. This paper explores the molecular mechanisms underlying the inflammatory response in cancer, focusing on the bidirectional interaction between immune cells and cancer cells. By examining key signaling molecules, transcription factors, and immune modulators involved in this crosstalk, the paper highlights potential therapeutic targets aimed at disrupting the inflammatory pathways that fuel carcinogenesis. Understanding the intricate relationship between chronic inflammation and cancer is crucial for the development of novel preventive and therapeutic strategies to combat inflammation-driven cancers.

Keywords: Chronic inflammation, cancer development, molecular crosstalk, tumor initiation, tumor progression, signaling pathways, NF-κB, JAK-STAT, MAPK, cytokines, chemokines, growth factors, reactive oxygen species, DNA damage, genomic instability, immune evasion, tumor microenvironment.

1.1 Introduction:

Chronic inflammation is a well-established contributor to the pathogenesis of various diseases, including cancer. Unlike acute inflammation, which is a protective and self-limiting response to injury or infection, chronic inflammation persists over long periods, often due to unresolved infections, autoimmune diseases, or environmental exposures. This prolonged inflammatory state creates a favorable microenvironment for tumor initiation, progression, and metastasis. The relationship between chronic inflammation and cancer is intricate, involving a range of cellular and molecular processes that promote carcinogenesis.(1)

At the cellular level, persistent inflammation alters the behavior of both immune and non-immune cells, facilitating tumorigenic changes. Inflammatory cells such as macrophages, neutrophils, and lymphocytes secrete various pro-inflammatory cytokines, growth factors, and chemokines that activate signaling pathways within neighboring cells. These signals not only support tumor growth and survival but also induce angiogenesis, tissue remodeling, and immune evasion—critical hallmarks of cancer. Furthermore, inflammatory mediators can induce the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), leading to oxidative stress, DNA damage, and subsequent

genomic instability, all of which are foundational for the development of cancer.

The NF-κB, JAK-STAT, and MAPK pathways are among the most prominent signaling networks activated during chronic inflammation. These pathways govern critical cellular processes, including cell proliferation, survival, migration, and the immune response. Importantly, the chronic activation of these pathways can create a positive feedback loop that sustains inflammation and accelerates tumor progression.(2)

This paper aims to explore the molecular crosstalk between chronic inflammation and cancer development, focusing on how inflammatory mediators and signaling pathways contribute to tumorigenesis. By understanding these complex interactions, we can identify potential therapeutic targets for disrupting the chronic inflammatory environment that promotes cancer growth. Such insights are essential for developing new strategies to prevent or treat inflammation-driven cancers, which represent a significant burden on public health worldwide.

1.2 Introduction to Chronic Inflammation and Cancer

Chronic inflammation is a long-lasting, persistent inflammatory response that occurs when the body's immune system remains activated due to unresolved injury, infection, or continuous exposure to harmful stimuli. Over time, this prolonged inflammation can shift from a protective mechanism to a damaging process that promotes tissue injury, cellular changes, and ultimately, cancer.(3) Chronic inflammation is increasingly recognized as one of the key contributors to the initiation, progression, and metastasis of cancer. Inflammatory processes create a tumor-supporting microenvironment, where the continuous release of inflammatory mediators accelerates the transformation of normal cells into malignant ones. The crosstalk between immune cells, tumor cells, and other components of the tumor microenvironment plays a crucial role in driving carcinogenesis. Understanding how chronic inflammation contributes to cancer is essential for developing novel therapeutic strategies aimed at disrupting this relationship.(4)

1.3 Differentiating Acute and Chronic Inflammation

Inflammation is a fundamental physiological response to tissue injury, infection, or harmful stimuli, but it can manifest in two distinct forms: acute and chronic inflammation. Acute inflammation is a short-term, protective response designed to eliminate the cause of injury or infection and repair damaged tissue.(5) It typically involves rapid activation of immune cells, such as neutrophils, and the release of pro-inflammatory cytokines and mediators like prostaglandins. This process usually resolves once the threat is eliminated. In contrast, chronic inflammation is prolonged and often unresolved, lasting for weeks, months, or even years. It is characterized by the persistent activation of immune cells, such as macrophages and T lymphocytes, and the continuous production of inflammatory mediators. While acute inflammation serves a protective role, chronic inflammation can lead to tissue damage, immune dysfunction, and an increased risk of various diseases, including cancer.(6)

1.4 Chronic Inflammation as a Contributor to Cancer Development

Chronic inflammation is a well-documented risk factor for several types of cancer. The prolonged inflammatory response creates an environment that promotes carcinogenesis through various mechanisms. Inflammatory cells infiltrate the tissue and secrete a wide range of cytokines, growth factors, and chemokines, which foster a microenvironment conducive to tumor growth.(7) These inflammatory mediators can activate key signaling pathways, such as NF-κB, MAPK, and JAK-STAT, which promote cell proliferation, survival, and resistance to apoptosis (programmed cell death). Additionally, chronic inflammation increases oxidative stress by producing reactive oxygen and nitrogen species (ROS and RNS), which can damage DNA, leading to mutations and genomic instability—key drivers of cancer. The cumulative effect of chronic inflammation creates a "vicious cycle," where the inflammatory response accelerates tumorigenesis, and the tumor itself can sustain or even amplify inflammation, further fueling cancer progression.(8)

1.5 Key Characteristics of Chronic Inflammation

Chronic inflammation is characterized by the continuous and prolonged presence of immune cells in tissues. Unlike acute inflammation, where neutrophils dominate the early response, chronic inflammation is primarily driven by macrophages, lymphocytes, and plasma cells. These immune cells release a variety of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, which contribute to

the persistence of inflammation. In addition to cytokines, growth factors like VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor) are also produced, supporting angiogenesis (the formation of new blood vessels) and tissue remodeling.(9) Chronic inflammation leads to tissue damage and fibrosis, with the activation of pathways that alter normal cellular functions. The altered tissue microenvironment, which includes changes in the extracellular matrix, promotes a pro-tumorigenic atmosphere, enhancing cancer cell survival, migration, and invasion. These key features of chronic inflammation are integral in creating conditions that favor cancer development and progression.(10)

1.6 Cellular and Molecular Mechanisms in Chronic Inflammation

Chronic inflammation involves intricate cellular and molecular mechanisms that sustain the inflammatory response and contribute to tumorigenesis. At the cellular level, immune cells like macrophages, neutrophils, and T lymphocytes infiltrate tissues and secrete inflammatory mediators. These cells not only respond to injury or infection but also alter the local tissue environment by releasing pro-inflammatory cytokines, chemokines, growth factors, and enzymes that promote cell proliferation, survival, and migration.(11) Molecularly, chronic inflammation results in the activation of several signaling pathways, such as NF-κB, MAPK, and JAK-STAT, which are crucial for controlling cellular processes like immune responses, tissue repair, and cell death. The persistent activation of these pathways in chronic inflammation leads to a maladaptive response, creating a microenvironment that fosters the accumulation of genetic mutations, cell transformation, and tumor progression. Moreover, reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced as by-products of inflammation, causing oxidative damage to DNA, proteins, and lipids, further enhancing the potential for tumorigenesis.(12)

1.7 Inflammatory Cells and Their Role in Tumorigenesis

Inflammatory cells play a significant role in both promoting and suppressing tumorigenesis, depending on the stage of cancer and the local tissue environment. In the context of chronic inflammation, cells such as macrophages, neutrophils, and dendritic cells are frequently recruited to the site of tissue damage or infection. Macrophages, particularly those that acquire a pro-inflammatory (M1) phenotype, secrete cytokines like TNF-α, IL-1, and IL-6 that can induce cellular proliferation and survival. (13)However, when macrophages switch to an anti-inflammatory (M2) phenotype, they promote tumor progression by fostering tissue remodeling, angiogenesis, and immune suppression. Neutrophils, while essential in combating infections, also contribute to tumor progression through the secretion of proteases and ROS, which can damage surrounding tissues and facilitate tumor invasion. Moreover, T lymphocytes, particularly regulatory T cells (Tregs), play a pivotal role in immune evasion by suppressing anti-tumor immune responses, allowing cancer cells to escape immune surveillance. The complex interplay of these inflammatory cells within the tumor microenvironment creates a permissive environment for tumor initiation, growth, and metastasis.(14)

1.8 Cytokines, Chemokines, and Growth Factors in Cancer

Cytokines, chemokines, and growth factors are crucial signaling molecules that mediate the effects of chronic inflammation in cancer development. Cytokines such as IL-6, IL-1β, and TNF-α play a central role in amplifying inflammation, promoting cell survival, and enhancing angiogenesis within tumors.(15) IL-6, for example, is a pleiotropic cytokine that activates the JAK-STAT pathway, promoting tumor cell proliferation, resistance to apoptosis, and immune evasion. Chemokines, like CCL2 and CXCL8, recruit immune cells to the tumor site, facilitating the formation of an inflammatory microenvironment that supports tumor growth and metastasis. Growth factors, such as vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), are secreted by inflammatory cells and tumor cells, driving angiogenesis and the formation of new blood vessels that supply nutrients to growing tumors. These signaling molecules collectively create a pro-tumorigenic environment by enhancing tumor cell survival, promoting tissue remodeling, and inhibiting immune surveillance. The persistent presence of these mediators in chronic inflammation ensures that the inflammatory response continually supports tumor progression.(16)

1.9 Signaling Pathways Activated by Inflammation in Cancer

Chronic inflammation activates several key signaling pathways that are integral to cancer development and progression. The NF-κB pathway is one of the most prominent, regulating immune responses, cell survival, and inflammation.(17) NF-κB activation in response to pro-inflammatory cytokines triggers the expression of genes that promote tumor cell proliferation, survival, and angiogenesis while suppressing apoptosis. The JAK-STAT pathway, often activated by cytokines such as IL-6 and IL-10, also plays a critical role in inflammation-driven cancer by promoting cell growth, survival, and immune evasion. The MAPK pathway, activated by growth factors and inflammatory mediators, enhances cell migration, survival, and invasion. These signaling pathways not only regulate the immune response but also create a feedback loop that sustains the chronic inflammatory state and accelerates cancer progression. Additionally, inflammation-induced activation of the PI3K/Akt pathway leads to enhanced cell survival and metabolic reprogramming, further supporting tumorigenesis. The continuous activation of these pathways leads to malignant transformation and metastasis, as well as resistance to conventional therapies.(18)

1.10 The NF-κB Pathway in Inflammation and Cancer

The NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway is a key molecular pathway activated in response to chronic inflammation and is often dysregulated in cancer. Under normal conditions, NF-κB is present in the cytoplasm in an inactive form bound to inhibitory proteins known as IκBs.(19) In response to inflammatory signals such as TNF-α, IL-1β, or pathogen-associated molecular patterns (PAMPs), IκBs are degraded, leading to the activation and translocation of NF-κB dimers (such as p65/p50) into the nucleus. Once in the nucleus, NF-κB initiates the transcription of genes involved in inflammation, immune response, cell proliferation, survival, and angiogenesis. In cancer, persistent activation of the NF-κB pathway leads to the continuous expression of pro-inflammatory cytokines and growth factors, which support tumor growth and metastasis. NF-κB activation also helps tumor cells evade apoptosis, enhances their resistance to chemotherapy and radiation, and promotes immune suppression within the tumor microenvironment. Therefore, targeting the NF-κB pathway presents a promising therapeutic strategy for cancers driven by chronic inflammation.(20)

1.11 JAK-STAT Pathway in Inflammation-Mediated Carcinogenesis

The JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway is a central signaling cascade activated by many pro-inflammatory cytokines, such as IL-6, IL-10, and interferons, which are commonly elevated in chronic inflammation. When cytokines bind to their respective receptors, JAKs are activated and subsequently phosphorylate STAT proteins, causing their dimerization and translocation to the nucleus.(21) In the nucleus, STAT proteins drive the transcription of genes involved in cell proliferation, survival, immune response modulation, and angiogenesis. In the context of inflammation-mediated carcinogenesis, prolonged activation of the JAK-STAT pathway results in the persistent expression of genes that promote tumor growth, resistance to cell death, and immune evasion. In particular, IL-6 signaling via JAK-STAT is often linked to cancer-associated inflammation and is implicated in promoting tumorigenesis by enhancing cellular proliferation, inhibiting apoptosis, and inducing immune suppression. Dysregulated JAK-STAT signaling is thus a key driver of cancer progression in inflammation-driven malignancies.(22)

1.12 MAPK Pathway in Chronic Inflammation and Cancer Progression

The MAPK (mitogen-activated protein kinase) pathway is a vital signaling network that mediates cellular responses to a variety of extracellular signals, including pro-inflammatory cytokines, growth factors, and environmental stressors. In chronic inflammation, persistent activation of the MAPK pathway promotes several key processes that contribute to cancer progression, including cell proliferation, survival, migration, and invasion. The pathway comprises several distinct cascades, such as the ERK (extracellular signal-regulated kinase), JNK (c-Jun N-terminal kinase), and p38 MAPK, each of which is activated by different inflammatory stimuli.(23) In cancer, the chronic activation of MAPK signaling helps tumor cells to overcome growth-regulatory signals, resist apoptosis, and metastasize to distant organs. Additionally, MAPK signaling enhances the production of inflammatory mediators that further fuel the chronic inflammatory response, creating a feed-forward loop that

accelerates tumor progression. Thus, the MAPK pathway serves as a crucial link between chronic inflammation and cancer metastasis, making it an important target for therapeutic interventions.(24)

1.13 Reactive Oxygen and Nitrogen Species in Cancer Development

During chronic inflammation, immune cells such as macrophages and neutrophils produce reactive oxygen species (ROS) and reactive nitrogen species (RNS) as part of the body's defense mechanisms. While these molecules are essential in killing pathogens and promoting tissue repair, their overproduction during prolonged inflammation leads to oxidative and nitrative stress, which can damage cellular components, including DNA, proteins, and lipids. DNA damage caused by ROS and RNS results in mutations and genomic instability, which are hallmark features of cancer initiation. Chronic oxidative stress also alters the tumor microenvironment by promoting angiogenesis, tissue remodeling, and immune suppression, all of which facilitate tumor progression.(25) Additionally, ROS and RNS can activate various oncogenic signaling pathways, such as NF-κB, MAPK, and JAK-STAT, enhancing tumor cell survival, proliferation, and invasion. The role of oxidative stress in driving cancer development underscores the importance of targeting ROS/RNS production and their downstream effects for cancer therapy.(26)

1.14 The Tumor Microenvironment and Chronic Inflammation

The tumor microenvironment (TME) is a complex and dynamic milieu composed of cancer cells, stromal cells, immune cells, extracellular matrix (ECM) components, and various signaling molecules. Chronic inflammation plays a central role in shaping the TME, creating conditions that support tumor initiation, growth, and metastasis. Inflammation-associated immune cells, such as macrophages, neutrophils, and T lymphocytes, infiltrate the TME and secrete a range of cytokines, growth factors, and proteases that influence tumor cell behavior and promote tumorigenesis.(27) These inflammatory mediators also promote angiogenesis, tissue remodeling, and immunosuppression within the TME. Furthermore, the persistent release of pro-inflammatory molecules results in a positive feedback loop, where cancer cells and stromal cells continue to produce signals that maintain chronic inflammation, creating a permissive environment for tumor progression. The TME influenced by chronic inflammation also facilitates cancer cell migration and invasion, contributing to metastasis. Understanding the role of chronic inflammation in shaping the TME is crucial for identifying potential therapeutic strategies to target inflammation within the TME and disrupt its pro-tumorigenic effects.(28)

1.15 Immune Evasion in Cancer: A Result of Chronic Inflammation

Immune evasion is one of the key hallmarks of cancer, and chronic inflammation plays a significant role in facilitating this process. While the immune system is responsible for detecting and eliminating abnormal cells, tumors often employ various strategies to escape immune surveillance. Chronic inflammation creates a microenvironment that supports immune suppression by recruiting immune cells such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), which inhibit the activity of effector T cells and natural killer (NK) cells. (29)Additionally, pro-inflammatory cytokines such as IL-10 and TGF-β, which are elevated during chronic inflammation, promote immune tolerance and further suppress anti-tumor immune responses. Inflammatory mediators also contribute to the expression of immune checkpoint molecules like PD-L1, which inhibit T cell activation and function. Furthermore, the constant presence of inflammatory signals can lead to the chronic activation of the immune system, resulting in immune exhaustion. This state of immune dysfunction allows tumor cells to evade detection and destruction, thereby enhancing their survival and metastatic potential. Therefore, targeting immune evasion pathways in inflammation-driven cancers represents an important therapeutic strategy.(30)

Molecular Mechanism	Role in Cancer Development	Key Molecules/Pathways
Inflammatory Mediators	Inflammatory mediators like cytokines, growth factors, and chemokines alter the tumor microenvironment and promote carcinogenesis.	IL-6, TNF-Î±, VEGF, EGF, CCL2, CXCL8

Cytokine Signaling	Pro-inflammatory cytokines such as IL-6 and TNF-Î± activate pathways that induce tumor cell proliferation and survival.	IL-6, TNF-Î±, IL-1Î²
Oxidative Stress	Chronic inflammation leads to increased reactive oxygen species (ROS) and nitrogen species (RNS) that damage DNA and promote mutations.	ROS, RNS
Tumor Microenvironment	The tumor microenvironment (TME) is influenced by immune cells and other stromal components that support cancer progression.	VEGF, FGF, ECM components
Immune Evasion	Cancer cells and the tumor microenvironment suppress immune responses, allowing cancer cells to evade immune surveillance.	TGF-Î², IL-10, PD-L1
Signaling Pathways (NF-ÎºB, JAK-STAT, MAPK)	Pathways like NF-ÎºB, JAK-STAT, and MAPK are activated by inflammation, leading to enhanced tumor growth, survival, and resistance to apoptosis.	NF-ÎºB, JAK-STAT, MAPK
Angiogenesis	Inflammation promotes angiogenesis, providing tumors with a blood supply to support growth and metastasis.	VEGF, EGF, HIF-1Î±
Genomic Instability	Persistent inflammation causes genomic instability through DNA damage, facilitating tumor initiation and progression.	p53, KRAS, TP53 mutations

Conclusion:

Chronic inflammation is a critical and dynamic contributor to cancer development, serving as both a promoter of tumor initiation and a facilitator of tumor progression. The molecular crosstalk between inflammatory cells, cytokines, chemokines, and growth factors creates a pro-tumorigenic microenvironment that drives cellular proliferation, survival, angiogenesis, and immune evasion. Key signaling pathways, including NF-κB, JAK-STAT, and MAPK, play pivotal roles in mediating the effects of chronic inflammation, leading to the activation of oncogenic processes and the accumulation of genetic mutations. Furthermore, the persistent production of reactive oxygen and nitrogen species exacerbates genomic instability, fueling carcinogenesis. The tumor microenvironment, shaped by chronic inflammation, enhances cancer cell survival, metastasis, and resistance to therapies, while promoting immune suppression and fostering immune evasion.

Given the complex interactions between chronic inflammation and cancer, targeting inflammation-associated pathways presents a promising approach for cancer prevention and therapy. A deeper understanding of the molecular mechanisms underlying inflammation-mediated carcinogenesis holds the potential to identify novel therapeutic targets and improve clinical outcomes. Ultimately, addressing the underlying inflammatory processes in cancer may help develop more effective and personalized treatment strategies that not only focus on the tumor itself but also on its inflammatory microenvironment, offering hope for more comprehensive and durable cancer therapies.

REFERENCES:

1. Mandal S, Mandal S. Topical Delivery of Sulfasalazine via Nanosponges-Loaded Hydrogels: A Novel Approach for Enhanced Psoriasis Management. International Journal of Multidisciplinary Science and Innovation. 2025 Apr 25:19-23.
2. Topi D, Dubey CK, Sharma S, Fasiha B, Mandal S. A Review of Plant-Based Natural Products for the Management of Diabetes: From Ethnobotany to Clinical Evidence. International Journal of Natural Products and Alternative Medicine. 2025 Mar 20:16-22.
3. Mandal S, Kumar M, Bhumika K, Ali S, Jahan I, Mandal S. Impact of Electronic Health Records and Automation on Pharmaceutical Management Efficiency: A Narrative Review. International Journal of Health Sciences and Engineering. 2025 Feb 17:21-36.
4. Kumar M, Manda S, Bhumika K, Ali S, Jahan I, Mandal S. Targeted Drug Delivery Systems in Oncology: A Review of Recent Patents and future directions. International Journal of Health Sciences and Engineering. 2025 Feb 17:37-57.
5. Mandal S. Advances and Future Prospects of Lipid-Based Nanocarriers in Targeted Cancer Therapy: A Comprehensive

Review. Current Cancer Drug Targets. 2025 May 13.

6. Chatterjee S, Ahamed IN, Aggarwal M, Mandal S, Mandal S. Bioadhesive Self-Nanoemulsifying Drug Delivery Systems (BSNEDDS): A Novel Strategy to Enhance Mucosal Drug Absorption and Bioavailability. International Journal of Multidisciplinary Science and Innovation. 2025 Apr 25:24-7.
7. Velraj M, Bhyan B, Mishram R, Padhy RP, Mandal S. Recent Advances in the Isolation and Characterization of Antimicrobial Compounds. International Journal of Natural Products and Alternative Medicine. 2025 Mar 20:23-9.
8. Kotnala M, Porwal P, Mandal S, Mandal S. The Role of Plant Metabolites in Enhancing Immunomodulatory Responses in Autoimmune Diseases. International Journal of Natural Products and Alternative Medicine. 2025 Mar 20:30-6.
9. Monisha R, Jaquline RS, Yadav K, Mandal S, Mandal S. Psychological Well-Being and Oral Health: The Role of Dentistry in Comprehensive Healthcare. International Journal of Integrative Dental and Medical Sciences. 2025 Mar 17:22-9.
10. Ismail A, KR PK, Mandal S. The Role of Oral Microbiota in Systemic Diseases: Bridging the gap between Dentistry and Medicine. International Journal of Integrative Dental and Medical Sciences. 2025 Mar 17:30-6.
11. Chatterjee S, Ahamed IN, Aggarwal M, Mandal S, Mandal S. Advances in Dental Biomaterials: Bridging Dentistry and Medicine for Improved Patient Outcomes. International Journal of Integrative Dental and Medical Sciences. 2025 Mar 17:1-6.
12. Kumar S, Mandal S, Bhyan B, Pandey A, Mishra R, Jain A. Digital Marketing Trends and Consumer Engagement: A Review. The International Journal of Humanities, Social Sciences and Business Management. 2025 Feb 27:6-10.
13. Mandal S, Mandal S. Cryptocurrency and the Future of Financial Markets: A Mini Review. The International Journal of Humanities, Social Sciences and Business Management. 2025 Feb 27:21-7.
14. Mandal S, Mandal S. Mesalamine Microemulsions for Crohn's Disease: A Review. International Journal of Health Sciences and Engineering. 2025 Feb 17:1-8.
15. Bhumika K, Ali S, Jahan I, Kumar M, Mandal S, Mandal S. Enhanced Bioavailability and Targeted Delivery of Mesalamine for Crohn's Disease Using Microemulsion Formulations. International Journal of Health Sciences and Engineering. 2025 Feb 17:16-20.
16. Mandal S, Mandal S. Design and Evaluation of Liposomal Carriers for Targeted Delivery of siRNA In Cancer Therapy. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:53-63.
17. Bhumika K, Mandal S. Exploring the Chemical Composition and Cardioprotective Properties of Plumeria obtusa Using Advanced LC-MS/MS and Computational Methods in a Rabbit Model of AdriamycinInduced Myocardial Injury. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:64-70.
18. Mandal S, Mandal S. Green Biomaterials from plants: Harnessing Nature for Sustainable Solutions. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:11-24.
19. Shiva K, Mandal S. Development and Characterization of Bioinspired Cationic Lipid Nanocarriers for Enhanced Anti-Cancer Vaccine Delivery and Tumor Inhibition: In Vitro and In Vivo Evaluation. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:71-7.
20. Mandal S, Mandal S. Strategic Design and Synthesis of Betulinic Acid Derivatives for Targeted Cancer Treatment. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:88-94.
21. Jahan I, Mandal S. Development of Multi-Functional Nanocarriers for Combined Chemo and Photothermal Cancer Therapy. Current Pharmaceutical Letters And Reviews. 2024 Oct 3:78-87.
22. Mandal S, Singh AP. Development and In-Vitro Characterization of Gentamycin Sulphate Nanoemulgel for Ophthalmic Applications. *International Journal of Drug Delivery Technology.* 2024;14(4):2347-58. doi: 10.25258/ijddt.14.4.56
23. Suraj Mandal, Murraya koenigii: A Source of Bioactive Compounds for Inflammation and Pain Management, Current Bioactive Compounds; Volume 21, Issue , Year 2025,

e15734072348822. DOI: 10.2174/0115734072348822250324073439

24. Jiyaul Hak, Iram Jahan, Nasiruddin Ahmad Farooqui, Atul Pratap Singh, Himanchal Sharma, Smriti Gohri, Anshu Gujjar, Suraj Mandal, Nanochips in the Field of Oncology: Advancements and Potential for Enhanced Cancer Therapy, Current Cancer Therapy Reviews; Volume 21, Issue , Year 2025, e15733947343855. DOI: 10.2174/0115733947343855241230115820
25. Iram Jahan, Jiyaul Hak, Suraj Mandal, Shadab Ali, Sayad Ahad Ali, Nasiruddin Ahmad Farooqui, Isoquinoline Quaternary Alkaloid (IQA) Nano-dressings: A Comprehensive Review on Design Strategies, Therapeutic Applications, and Advancements in Transdermal Delivery for Chronic Wound Management, Recent Advances in Drug Delivery and Formulation; Volume 19, Issue , Year 2025, e26673878330005. DOI: 10.2174/0126673878330005250326060103
26. Mandal S, Vishvakarma P. Nanoemulgel: A Smarter Topical Lipidic Emulsion-based Nanocarrier. *Indian J of Pharmaceutical Education and Research*. 2023;57(3s):s481-s498.
27. Mritunjay Kumar Ojha, Nalluri Satish Kumar, Umesh Kumar Sharma, Prakash Gadipelli, Suraj Mandal, Farah Deeba, Monalisa Khuntia, Hariballav Mahapatra (2024) Exploring the Potential of Artificial Intelligence in Optimizing Clinical Trial Design for More Efficient Drug Development. *Library Progress International*, 44(3), 9498-9510.
28. Mandal S, Jaiswal DV, Shiva K. A review on marketed Carica papaya leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. *International Journal of Pharmaceutical Research*. 2020 Jul;12(3).
29. Mandal S, Bhumika K, Kumar M, Hak J, Vishvakarma P, Sharma UK. A Novel Approach on Micro Sponges Drug Delivery System: Method of Preparations, Application, and its Future Prospective. Indian J of Pharmaceutical Education and Research. 2024;58(1):45-63.
30. Mandal S, Vishvakarma P, Bhumika K. Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders. Curr Drug Res Rev. 2023 Dec 29. doi: 10.2174/0125899775266634231213044704. Epub ahead of print. PMID: 38158868.

*****